SCHEMBL19408052

SCHEMBL19408052

COc1ccc(CCNC(=S)N2CCc3cc(OC)c(OC)cc3C2)cc1OC

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 7/20 0.60
▸ MEN1 O00255 6/20 0.60
▸ GAA P10253 2/20 0.60
▸ CYP1A2 P05177 1/20 0.60
▸ CYP3A4 P08684 1/20 0.60
▸ CYP2C9 P11712 1/20 0.60
▸ CYP2C19 P33261 1/20 0.60
▸ MAPT P10636 6/20 0.59
▸ ALDH1A1 P00352 5/20 0.59
▸ SMN1; SMN2 Q16637 4/20 0.59
▸ HTT P42858 3/20 0.59
▸ LMNA P02545 3/20 0.59
▸ RAB9A P51151 2/20 0.59
▸ KDM4E B2RXH2 2/20 0.58
▸ MAPK1 P28482 1/20 0.55
▸ TAAR1 Q96RJ0 1/20 0.55
▸ NPC1 O15118 2/20 0.54
▸ DHCR7 Q9UBM7 1/20 0.54
▸ NPSR1 Q6W5P4 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31657812 0.89 MEN1 (0.67) KMT2AMEN1GAACYP1A2CYP3A4
SCHEMBL5708728 0.89 MEN1 (0.67) KMT2AMEN1GAACYP1A2CYP3A4
SCHEMBL5708825 0.83 MEN1 (0.77) KMT2AMEN1GAACYP1A2CYP3A4
SCHEMBL19376013 0.81 KMT2A (0.65) KMT2AMEN1GAACYP1A2CYP3A4
SCHEMBL5334297 0.77 MEN1 (0.81) KMT2AMEN1GAACYP1A2CYP3A4
SCHEMBL14640683 0.77 MAPT (0.72) KMT2AMEN1GAACYP1A2CYP3A4
SCHEMBL5708725 0.77 MAPT (0.49) KMT2AMEN1GAACYP1A2CYP3A4
SCHEMBL19376073 0.76 POLB (0.56) KMT2AMEN1GAACYP1A2CYP3A4
SCHEMBL31657813 0.76 POLB (0.56) KMT2AMEN1GAACYP1A2CYP3A4
SCHEMBL5592518 0.75 KMT2A (0.63) KMT2AMEN1GAACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10457676-B2 Capsazepine analogs for the treatment of cancer and other proliferative diseases THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-10-29 — — US disclosed
EP-3549582-A2 NOVEL CAPSAZEPINE ANALOGS FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES The Board of Regents of The University of Texas System (US) 2019-10-09 — — EP disclosed
US-20170275280-A1 NOVEL CAPSAZEPINE ANALOGS FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170275280-A1 NOVEL CAPSAZEPINE ANALOGS FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES TRPV1, TRPV5, CNR2 KMT2A 2918/4885MEN1 3654/4885GAA 2515/4885
US-10457676-B2 Capsazepine analogs for the treatment of cancer and other proliferative diseases TRPV1, TRPV5, CNR2 KMT2A 2511/4885MEN1 3228/4885GAA 2126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback